Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2020-12-04 Legal Proceedings Report
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Wyniki badania klinicznego dotyczące wpływu metforminy na farmakokinetykę agonisty receptora GPR40 - CLP207280 w leczeniu cukrzycy typu II oraz neuropatii cukrzycowych - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document is written in Polish and references previous 'raport bieżący' (current report) numbers and dates. It discusses the positive results of a Phase I clinical trial for a drug (CLP207280) concerning its pharmacokinetics when combined with metformin, which is favorable for future clinical development plans. This type of announcement, detailing specific scientific or clinical progress updates that are material to the company's operations but do not fit neatly into standard financial reports (like 10-K or ER), is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update if the context was different. Given the nature of reporting clinical trial progress and interactions with regulatory bodies (implied by the mention of NCBR funding), RNS serves as the most appropriate general regulatory announcement category when a more specific code like 'LTR' (Legal Proceedings) or 'CAP' (Financing) does not apply. It is a specific update, not a full report or a management discussion.
2020-12-04 Polish
Wyniki badania klinicznego dotyczące wpływu pokarmu na farmakokinetykę agonisty receptora GPR40 - CLP207280 w leczeniu cukrzycy typu II oraz neuropatii cukrzycowych - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement (1123 characters) written in Polish, referencing a previous report (raport bieżący nr 21/2020) and providing an update on clinical trial results for a drug (CLP207280). It details specific scientific findings (pharmacokinetics, food effect) related to a drug development program (GATE project) and mentions future financing/progress updates. This type of specific, non-periodic operational update, especially concerning clinical trials or R&D progress, does not fit neatly into the primary financial report categories (10-K, IR, ER). Since it is a specific operational/scientific update that doesn't match M&A (TAR), Capital (CAP), or Director changes (MANG), it falls best under the general 'Regulatory Filings' category as a miscellaneous, specific corporate disclosure, or potentially an 'RPA' if it were announcing the release of a more detailed report, but here it *is* the update itself. Given the context of clinical trial progress updates, which are often mandatory disclosures but lack a specific code, RNS (Regulatory Filings) is the most appropriate fallback.
2020-12-02 Polish
CELON PHARMA RAPORT Q3 2020
Interim / Quarterly Report Classification · 1% confidence The document is a 'Raport kwartalny' (Quarterly Report) for Celon Pharma S.A. for the third quarter of 2020. It contains detailed information on company structure, management, capital, and accounting policies, which are standard components of an interim financial report. It is not a mere announcement (RPA) as it contains substantive financial and operational data. Therefore, it is classified as an Interim/Quarterly Report. 9M 2020
2020-11-30 Polish
Podpisanie umowy z NCBR o dofinansowanie projektu rozwoju CPL’116 w leczeniu idiopatycznego zwłóknienia płuc na kwotę 18,7 mln zł - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is very short (979 characters) and references a previous current report ('raport bieżący nr 28/2020'). It announces that the company has received knowledge about the signing of a co-financing agreement ('podpisaniu przez NCBR umowy o dofinansowanie') for a specific project, detailing the total cost and the grant amount. This is a specific update regarding financing/funding for a project, which aligns best with the Capital/Financing Update category (CAP). It is not a full report (like 10-K or IR), nor is it a general regulatory announcement (RNS) or a dividend notice. It is a specific update on capital/funding received.
2020-11-26 Polish
Podpisanie umowy z NCBR o dofinansowanie projektu rozwoju CPL’36 w leczeniu dyskinez w chorobie Parkinsona na kwotę 8,1 mln zł - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a brief announcement (length 997 chars) referencing a previous current report (raport bieżący nr 27/2020) regarding the signing of a co-financing agreement with the National Centre for Research and Development (NCBR) for a project. It details the total cost (17.0 million PLN) and the grant amount (8.1 million PLN). Since this is a specific update on financing/grants related to a project, it fits best under Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because it is highly specific to a financing event, nor is it an Earnings Release (ER) or a full report (10-K/IR).
2020-11-26 Polish
Piąte wezwanie akcjonariuszy Celon Pharma S.A. do złożenia dokumentów akcji w Spółce - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a formal notice in Polish from the Management Board of Celon Pharma S.A. ("Emitent") calling upon shareholders to submit their physical share certificates for dematerialization and registration with the National Securities Depository (KDPW S.A.). It cites specific Polish legislation regarding the mandatory dematerialization of shares and states that the validity of the physical share documents expires on March 1, 2021. This action relates directly to the company's capital structure and the formal process of changing how shares are held. This fits best under 'Capital/Financing Update' (CAP) as it mandates a change in the capital structure mechanism (from physical certificates to electronic registration). It is not a standard financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It is a mandatory corporate action related to capital.
2020-11-23 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.